Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Cyclerion Therapeutics, Inc.

$23.52

0 (0%)

D 33Pipeline Score Richly Valued Pharma · Clinical
Market Cap
110.11 M
EPS
-1.43
P/E Ratio
-
Value Trade
30.45 K
453.41 %
Week
500 %
1 Month
623.69 %
3 Month
1,522.07 %
6 Month
-95.02 %
5 Year
-99.19 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
62.49 K
52 Week Range
1.03 - 26.88
% held by Insiders
64.01 %
% held by Institutions
-
Enterprise Value
108.71 M
Total Shares
4.68 M
Short %
3.12 %
Float Shares
3.26 M
Company Description
HQ: 301 BINNEY STREET, CAMBRIDGE, ...
Employees:1
https://www.cyclerion.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Cyclerion Therapeutics, Inc.

117Total events
3Upcoming
38Tier-1 (high impact)
2019 – 2027Coverage

Upcoming catalysts 2

TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2First Patient Dosed
Subscribe to view catalyst details
CYC-126

Event history 2

TBD
◆Timing GuidancePresentation
Subscribe to view catalyst details
TBD
◆Trial InitiationCYC-126Trial
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2023-12-31
CY6463 (oral, once-daily sGC stimulator)
Phase 2a topline data readout
Phase 2a
—
–
–
–
2023-12-31
CY6463 (oral, once-daily sGC stimulator)
Phase 2a topline data readout
Phase 2a
—
–
–
–
2023-12-31
CY6463 (oral, once-daily sGC stimulator)
Phase 2a topline data readout
Phase 2a
—
–
–
–
Unlock 5 more historical catalysts
Drug Pipeline Intelligence
D33
Pipeline Score
$15M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 47%
Micro Cap
(rank 404 of 760)
Percentile Rank
Cyclerion Therapeutics, Inc. faces pipeline headwinds (33/100), with $2.9B risk-adjusted pipeline value, led by IW-1973 in Diabetes Mellitus, Type 2 (Phase 2), across $105B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IW-1973
Small molecule
Completed		Diabetes Mellitus, Type 2Phase 2NCT029065799% $2.5B COMPLETED 37 - -Mar 17, 2017 -Apr 16, 2020
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CY6463
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS)
Phase 2a
2022-08-09

improvements were seen across a range of assessments, including mitochondrial disease-associated biomarkers such as lactate and GDF-15, a broad panel of inflammatory biomarkers, cerebral blood flow, and functional connectivity between neural networks.

Read More

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lact

Read More
CY6463
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS)
Phase 2a
2022-08-09

improvements were seen across a range of assessments, including mitochondrial disease-associated biomarkers such as lactate and GDF-15, a broad panel of inflammatory biomarkers, cerebral blood flow, and functional connectivity between neural networks.

Read More

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lact

Read More
CY6463
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS)
Phase 2a
2022-08-09

improvements were seen across a range of assessments, including mitochondrial disease-associated biomarkers such as lactate and GDF-15, a broad panel of inflammatory biomarkers, cerebral blood flow, and functional connectivity between neural networks.

Read More

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lact

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CYCN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
CYCN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CYCN ranks across every disease it competes in
Competitive Position is a premium feature
See how CYCN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial